Oceania

Novel therapy for pancreatic cancers, targeting molecular foundation

Dr Michael Lee is an experienced medical oncologist, sub-specialising in gastrointestinal cancers and neuroendocrine tumours at the Peter MacCallum Cancer Centre.

He plays a key role in molecular tumour boards at VCCC Alliance (Victorian Comprehensive Cancer Centre) and MPCCC (Monash Partners Comprehensive Cancer Consortium), ensuring the accurate and effective use of precision medicine in cancer care across the state.

Genetics and Environmental Factors of Glaucoma & Myopia

Professor David Mackey’s original research, over more than 30 years into the genetics of glaucoma and in the fields of optic atrophy and congenital cataract, has received constant professional accolades, attracted ongoing research funding and led to his publication of more than 400 peer-reviewed papers.

Paediatric obesity prevention, nutrition and dietetics

Leveraging a systems-based and collaborative approach, Dr Littlewood over the past 25 years has driven research and data outcomes in the area of health and wellbeing. Dr Littlewood leads a dedicated team focused on making healthy happen for all Queenslanders, with a particular focus on improving health outcomes for the next generation. 

Antimicrobial technologies & drug delivery platforms

Dr Aaron Elbourne is an ARC DECRA Fellow, Jack Brockhoff ECR Fellow, and Associate Professor within the School of Science at STEM Hub. A leader in nanomaterials, soft matter science, and interface research, Aaron’s work addresses critical challenges in health and the environment.

With a strong focus on translational research, Aaron’s work bridges the gap between fundamental science and practical applications. His leadership in creating innovative technologies, fostering academic-industry partnerships, and empowering future researchers underscores his commitment to advancing science and creating a meaningful impact.

RESEARCH IMPACT: 35 years of kids’ health research

The Kids Research Institute Australia is one of the largest and most successful medical research institutes in Australia. The Institute has created a blueprint that brings together community, researchers, practitioners, policy makers and funders, who share our vision to improve the health and wellbeing of children through excellence in research. In November 2025, The Kids Research Institute Australia celebrated 35 years of bold ideas, groundbreaking research, and the people who find answers to the big questions about better health outcomes for children and families.

CASE STUDY: Transforming surgical waitlist into a ‘preparation list’

The DIAMONDS initiative aims to transform the surgical waitlist into a “preparation list,” enabling healthcare professionals to optimise patient care in the months leading up to elective surgery starting at pre-admission phase.

Patients are will be able to complete pre-admission forms online, receive timely updates, and access educational resources to ensure thorough preparation. This will allow staff to spend more time with patients.

Systems genetics to determine risk of developing diabetes complications

Professor Morahan invented the term “Systems Genetics” for the science field that examines how genetic variants can affect whole networks of genes and whole systems; there are now several laboratories and institutes of systems genetics around the world. He also developed the next-generation genetic resource, The Gene Mine, the most powerful of its type in the world, used globally in rapid mapping and identification of genes. Collaborators nationally and internationally have tested The Gene Mine for traits and diseases in which they specialise.

Pancreatic and lung cancers driven by mutations in the cancer gene KRAS

Dr Mara Zeissig is a recently appointed Lab Head within the Tumour Inflammation and Immunotherapy Program at the South Australian immunoGENomics Cancer Institute (SAiGENCI).
Her research focuses on studying immune evasion mechanisms in lung and pancreatic cancers to identify novel ways to increase response to immunotherapy. Her expertise is in genetically engineered mouse models of lung cancer, CRISPR-Cas9 screening technologies and T cell based immunotherapies (e.g Checkpoint inhibitors).

Nutraceutical and pharmacological intervention in neurological disorders

Dr Virginie Lam is a neuroscientist and cerebrovascular biologist with over 15 years of research experience, including more than seven years post-PhD. She co-leads the Neurovascular and Metabolic Diseases Laboratory at the Curtin Medical Research Institute and holds an affiliate appointment at the Perron Institute for Neurological and Translational Science. Her research focuses on the interface between neurovascular health, cognitive function, and therapeutic translation in neurodegenerative disorders.

Liver cancer biomarkers, risk prediction & progression

Dr. Rodrigo Carlessi is an expert in Cancer Genomics and Molecular Biology, with an extensive track record in liver cancer research. He leads the Cancer Genomics Group within the Liver Disease and Regeneration Laboratory at the Curtin Medical Research Institute. He has an impressive publication record, with 43 manuscripts that have collectively garnered over 2,680 citations. His research leverages cutting-edge genomics and transcriptomics technologies, as well as long-read DNA sequencing, to explore mechanisms, identify biomarkers, and develop therapeutic targets in liver disease and cancer.

Scroll to top